Good afternoon and welcome to Markets Desk, your midday read on what's moving markets and the stories behind the numbers.
SpaceX has officially gone public, and the IPO is drawing intense scrutiny from investors eyeing what comes next. The lesson from the listing is blunt: a compelling narrative can carry a company across the finish line regardless of traditional valuation metrics. That sets a precedent worth watching as Anthropic and OpenAI prepare their own entries into public markets.
Turning to pharmaceuticals, Pfizer remains a name that surfaces whenever investors talk about long-horizon value plays. The company carries genuine brand weight and a deep pipeline, but calling any single equity a ticket to generational wealth requires a hard look at patent cliffs, competitive pressure from generics, and the post-pandemic revenue hangover that has weighed on the stock for two years running.
And in the electric vehicle space, the question being asked across trading desks is whether two thousand twenty six marks a genuine inflection point for EV names or simply another false dawn. Demand softness, margin compression, and a slower-than-expected charging infrastructure buildout have kept institutional money cautious, though some analysts argue the setup for a recovery is quietly forming beneath the surface.
That's the tape. Markets Desk, signing off the floor.
